Press Releases

Press Releases

September 18, 2020
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® technology platform, today announced that on
Additional Formats
September 2, 2020
CytomX Therapeutics to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody ® therapeutic technology platform, announced
Additional Formats
July 28, 2020
CytomX Therapeutics to Announce Second Quarter 2020 Financial Results
-Teleconference Scheduled for August 6, 2020, at 5:30 p.m. ET- SOUTH SAN FRANCISCO, Calif. , July 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics
Additional Formats
May 28, 2020
CytomX Therapeutics to Participate at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , May 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody ® therapeutic technology platform, announced
Additional Formats
Displaying 1 - 10 of 27